ABL Diagnostics Strengthens Strategic Supplier Agreements to Support Accelerated Growth

The renewed and expanded agreements provide improved commercial conditions, including more competitive pricing, optimized ...
Morningstar

ABL Diagnostics Informs the Market of a Non‑Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Reverse Merger

ABL Diagnostics Informs the Market of a Non‑Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Reverse Merger The contemplated transaction remains subject to due ...
Business Wire

ABL DIAGNOSTICS, Key Player in the Diagnosis of Infectious Diseases by Genotyping, Presents Its Development Plan to the Financial Community

PARIS--(BUSINESS WIRE)--Regulatory News: ABL DIAGNOSTICS (Euronext Paris, FR001400AHX6, ABLD) today presents its ABLDX 2027 medium-term development plan to the financial community. Formed from the end ...
The Globe and Mail

ProPhase Labs Announces Proposed Reverse Merger with ABL

Prophase Labs ( (PRPH)) just unveiled an update. ProPhase Labs, Inc. announced that it has entered into a non-binding letter of intent for a proposed reverse merger with Advanced Biological ...
Seeking Alpha

ABL Diagnostics Informs the Market of a Non‑Binding Letter of Intent Between ABL S.A. and ProPhase Labs (Nasdaq: PRPH) for a Proposed Reverse Merger

The contemplated transaction remains subject to due diligence, definitive agreements, regulatory approvals and Nasdaq listing requirements; no change to ABL S.A.’s control over ABL Diagnostics at this ...